Gilead Sciences at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Gilead Sciences takes part in 2 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8063. Its program centres on antibody-drug conjugates in breast and gynaecological cancers. It also covers sacituzumab govitecan as a first-line option for metastatic triple-negative breast cancer, whatever the tumour's PD-L1 status, and what new approvals mean for everyday practice.
| Organization | ESMO 2026 Attendance |
|---|---|
US biopharmaceutical company whose oncology unit, with cell-therapy arm Kite, markets antibody-drug conjugates and CAR T therapies. | Booth Exhibiting at Booth 8063 Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 18:30–20:00 Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers |
Instantly find 20 buyers from Gilead Sciences
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction